$NGNE

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

H.C. Wainwright cut its Neurogene (NASDAQ:NGNE) price target to $65 from $70 but kept a Buy rating. The firm cited Neurogene’s Process Performance Qualification campaign, expected to finish by year-end 2026, and a recent follow-on offering raising about $144 million gross and $134.8 million net. Pro forma cash is about $360.2 million, extending runway into Q1 2029.

Neurogene Inc. (NGNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participan

Neurogene Inc. (NGNE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ngne-june2026cmpoxunderwri.htm EX-1.1 Document NEUROGENE INC. (a Delaware corporation) 3,500,000 Shares of Common Stock Pre-Funded Warrants to purchase up to 666,666 shares of Common Stock UNDERWRITING AGREEMENT June 30, 2026 Leerink Partners LLC Stifel, Nicolaus & Compa